AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference.PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII), announced that Alan P. Timmins, AVI's president and COO, will present the company's biodefense therapeutic development strategy and progress at the Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference. The conference will be held at the St. Regis Hotel in New York; AVI's presentation will take place today at 8:55 a.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT in the Fountainebleau Room. "We see an important role for our rapid response antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). therapeutics in potentially protecting the nation's health in the event of a bioterror attack," Timmins said. "I'm looking forward to discussing the various applications of our technology at the upcoming conference." In January 2006, AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. gained approval for an $11 million allocation as part of the Defense Appropriations Act to develop therapeutic agents against Ebola, Marburg and dengue viruses, as well as countermeasures for anthrax exposure and antidotes for ricin toxin. This funding allocation more than doubled the allocation approved by the Department of Defense in the previous fiscal year. The company anticipates receiving the funding as agreed-upon research benchmarks are met in the future. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE(R) antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , hepatitis C virus
"Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion